Anifrolumab denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Imposes Quantity Limits on Anifrolumab

Quantity limit (QL) denials for anifrolumab occur when the requested quantity — number of vials, dosing frequency, or supply duration — exceeds what Cigna's formulary designates as the standard authorized amount per coverage period. For a fixed-interval intravenous infusion drug like anifrolumab, quantity limits are typically defined per infusion cycle or per dispensing period. A QL denial does not mean the drug is non-covered; it means the requested quantity exceeded the plan's preset limit and requires additional justification or an exception.

## Why This Denial Is Appealable

If the prescribed regimen follows the FDA-approved prescribing label, the quantity limit exception appeal is straightforward: the FDA-approved dosing schedule is the standard of care. Any plan limit that conflicts with the FDA-approved regimen is clinically unjustifiable, and external reviewers consistently recognize this. If the prescriber has recommended a schedule that varies from the label for a documented clinical reason, that rationale should be explicitly stated.

## Your Federal Appeal Rights

• Internal appeal: File a written quantity-limit exception request with supporting documentation. This is an adverse benefit determination subject to full-and-fair review under ERISA §503 and ACA §2719.
• External review: If denied internally, independent external review is available — approximately four months from the final internal denial date. Expedited review is available for urgent clinical situations.
• Practical tip: Clarify in the appeal whether the quantity requested exactly matches the FDA-approved prescribing schedule. If it does, lead with the prescribing label as Exhibit A.

## Documentation to Gather

1. FDA prescribing label — the current full prescribing information for anifrolumab showing the approved dosing schedule. Confirm that the quantity requested on the prescription corresponds exactly to what the label authorizes. 2. Prescription and order documentation — the actual prescription showing the prescribed regimen and the quantity requested in the claim. 3. Prescriber letter — brief attestation from the rheumatologist confirming the prescribed quantity aligns with the FDA-approved regimen (or explaining any clinically necessary deviation). 4. Cigna's quantity-limit policy — identify the specific limit from Cigna's formulary or coverage policy documentation and note where it conflicts with the label. 5. Infusion administration records — if the patient has already received doses, include administration logs showing the established schedule.

## Criteria-Mapping Structure

Your appeal should center on a side-by-side comparison: the FDA-approved dosing schedule on one side, the quantity requested in the claim on the other. Where they match, state that plainly and attach the label as evidence. Where Cigna's quantity limit is more restrictive than the label, document the discrepancy explicitly. A concise, factual comparison is more persuasive than a lengthy narrative for this type of denial.